Pennsylvania to Cover Blood-Based Cancer Screenings
State legislation will eliminate out-of-pocket costs for blood-based colorectal cancer tests starting December 21, 2026.
Updated on Oct. 29, 2026 in Cancer
Live Poll
Should insurance plans be required to cover all FDA-approved non-invasive cancer screenings at no cost?
Pennsylvania will implement a new law on December 21, 2026, requiring state-regulated health insurance and Medicaid plans to cover blood-based colorectal cancer screenings without cost-sharing. This mandate aims to increase participation in preventative care for approximately 2 million eligible state residents.
Why it matters
The legislation addresses screening delays caused by federal guideline updates and seeks to boost early detection by removing financial barriers to non-invasive testing options. By aligning state requirements with established medical standards, the law ensures broader access to preventative cancer monitoring.
The mandate covers approximately 2 million screening-eligible residents in Pennsylvania who will no longer face cost-sharing for the Shield blood test. This test is specifically indicated for individuals aged 45 years and older.
The players
American Cancer Society
This nationwide organization provides evidence-based research and guidelines for cancer prevention and screening protocols.
National Comprehensive Cancer Center
This alliance of leading cancer centers develops clinical practice guidelines to improve the quality and effectiveness of cancer care.
The details
House Bill 1123 removes out-of-pocket expenses for the Shield test, a methylation partitioning cell-free DNA blood draw performed during routine appointments. Patients who receive a positive result from the blood-based screen will be referred for a follow-up diagnostic colonoscopy.
Timeline
December 21, 2026: The new law is scheduled to take effect.
The Big Picture
Pennsylvania House Bill 1123 aligns state-level health policy with national clinical standards for colorectal cancer detection. The law extends the reach of preventive medical protocols by mandating coverage for emerging non-invasive diagnostic technologies.
Residents aged 45 and older will gain access to cost-free blood-based screenings, offering a non-invasive alternative to traditional colonoscopies. This change reduces out-of-pocket expenses for those currently eligible for routine colorectal cancer monitoring.
The takeaway
Early detection remains the most effective tool in managing colorectal cancer outcomes for aging populations. Residents should consult their healthcare providers to determine if a blood-based screening test is appropriate for their specific risk profile starting in 2026.
What happens next
The legislation is scheduled to take effect across all state-regulated insurance and Medicaid plans on December 21, 2026.
Further reading
For more on preventative healthcare initiatives, see the Pennsylvania Cancer section.
Live Poll
Should insurance plans be required to cover all FDA-approved non-invasive cancer screenings at no cost?
